Referred to the House Committee on the Judiciary.
The bill creates an Interagency Task Force on Patents to formalize coordination between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) specifically for patents and patent-related decisions concerning human drugs and biological products. It requires a memorandum of understanding, specifies membership drawn from both agencies, and enumerates activities including sharing information about agency processes, new approvals, prior art, and certain non-public communications when appropriate.
Transparency vs. confidentiality: liberals want stronger public-interest reporting and safeguards, conservatives prioritize stricter protection of trade secrets and limited sharing.
Relative to its intended legislative type, this bill is a well-targeted administrative/operational statute that establishes a statutory interagency task force, prescribes specific coordination functions between the USPTO and FDA for human drugs and biological products, and includes confidentiality safeguards and a substantive reporting requirement.
The bill creates an Interagency Task Force on Patents to formalize coordination between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) specifically for patents and patent-related decisions concerning human drugs and biological products.
It requires a memorandum of understanding, specifies membership drawn from both agencies, and enumerates activities including sharing information about agency processes, new approvals, prior art, and certain non-public communications when appropriate.
The bill requires confidentiality protocols (including 30-day notice to drug sponsors before sharing certain information), separation of shared information from pending patent applications, and identification of remedies for inadvertent disclosure.
On substance this is a narrowly targeted, technical interagency coordination bill with limited fiscal impact and built-in procedural safeguards, characteristics that historically make enactment more likely than sweeping or partisan measures. Main obstacles are potential pushback from industry over confidentiality and trade-secret risks, legal limits on sharing certain FDA information, and the need for administrative implementation without additional funding. If stakeholders are not strongly opposed and agencies cooperate, passage is plausibly achievable; if legal/industry concerns are substantial, they could slow or alter the bill.
Relative to its intended legislative type, this bill is a well-targeted administrative/operational statute that establishes a statutory interagency task force, prescribes specific coordination functions between the USPTO and FDA for human drugs and biological products, and includes confidentiality safeguards and a substantive reporting requirement.
Transparency vs. confidentiality: liberals want stronger public-interest reporting and safeguards, conservatives prioritize stricter protection of trade secrets and limited sharing.
These are examples from the analysis, not a ranked list of the most-affected groups.
Transparency vs. confidentiality: liberals want stronger public-interest reporting and safeguards, conservatives prioritize stricter protection of trade secrets and limited sharing.
A mainstream liberal would likely view the bill as a potentially useful step toward improving patent quality for drugs and biologics by giving patent examiners access to FDA-held scientific and regulatory information that could reveal prior art or limit improper patenting.
They would welcome measures that could reduce frivolous or “evergreening” patents that raise drug prices, while watching the confidentiality provisions and sponsor-notice rules closely.
They would be cautiously optimistic but want stronger public-interest protections, transparency, and safeguards against industry influence.
A centrist/moderate would likely see the bill as a pragmatic administrative measure to improve interagency information flow where scientific and regulatory expertise at the FDA could assist patent examiners, while being attentive to implementation risks.
They would appreciate the MOU, defined membership, confidentiality protocols, and the 4-year report as appropriate oversight and evaluation mechanisms.
Their support would depend on assurances about limited scope, minimal procedural delays, clear data protections, and a cost/benefit analysis.
A mainstream conservative would likely be skeptical of creating a standing interagency mechanism that increases coordination between two large federal agencies, viewing it as potential regulatory expansion and administrative bloat.
They would worry about protection of proprietary business information, increased opportunities for government mishandling of confidential data, and potential new hurdles or delays for patent applicants.
While valuing strong property rights and accurate patents, they would prefer any information-sharing to be narrowly constrained and to avoid new processes that could weaken patent holders’ legal protections.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance this is a narrowly targeted, technical interagency coordination bill with limited fiscal impact and built-in procedural safeguards, characteristics that historically make enactment more likely than sweeping or partisan measures. Main obstacles are potential pushback from industry over confidentiality and trade-secret risks, legal limits on sharing certain FDA information, and the need for administrative implementation without additional funding. If stakeholders are not strongly opposed and agencies cooperate, passage is plausibly achievable; if legal/industry concerns are substantial, they could slow or alter the bill.
The bill has not accumulated any surfaced votes yet.
Transparency vs. confidentiality: liberals want stronger public-interest reporting and safeguards, conservatives prioritize stricter protec…
On substance this is a narrowly targeted, technical interagency coordination bill with limited fiscal impact and built-in procedural safegu…
Relative to its intended legislative type, this bill is a well-targeted administrative/operational statute that establishes a statutory interagency task force, prescribes specific coordination functions between the USPT…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.